A Phase III Double-blind, Extension, Placebo-controlled Parallel Group Safety and Efficacy Trial of BI 10773 (10 and 25mg Once Daily) and Sitagliptin (100mg Once Daily) Given for Minimum 76 Weeks (Incl. 24 Weeks of Preceding Trial) as Monotherapy or With Different Back-ground Therapies in Patients With Type 2 Diabetes Mellitus Previously Completing Trial 1245.19, 1245.20 or 1245.23
A Phase III Double-blind, Extension, Placebo-controlled Parallel Group Safety and Efficacy Trial of BI 10773 (10 and 25mg Once Daily) and Sitagliptin (100mg Once Daily) Given for Minimum 76 Weeks (Incl. 24 Weeks of Preceding Trial) as Monotherapy or With Different Back-ground Therapies in Patients With Type 2 Diabetes Mellitus Previously Completing Trial 1245.19, 1245.20 or 1245.23
This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.
Inclusion criteria:
Exclusion criteria:
Mount Pearl, Newfoundland and Labrador, Canada
St. John's, Newfoundland and Labrador, Canada
Haerbin, China
Saint Ingbert/Oberwürzbach, Germany
Schauenburg, Germany
Maharashtra, India
Co. Cork, Ireland
Co. Galway, Ireland
Co. Wexford, Ireland
Co. Wexford, Ireland
Chuo-ku, Tokyo, Japan
Chuo-ku, Tokyo, Japan
Kamakura, Kanagawa, Japan
Minato-ku, Tokyo, Japan
Suita, Osaka, Japan
Ube, Yamaguchi, Japan
Urasoe, Okinawa, Japan
Urasoe, Okinawa, Japan
Taoyuan County, Taiwan